Premium Nahrungsergänzungsmittel | artgerecht

Oncolytic Virus Therapy: Explanation & Application

Oncolytic virus therapy is an innovative cancer treatment that uses specially engineered viruses to selectively infect and destroy tumor cells while sparing healthy tissue.

Regular tips about health Regular tips about health

Things worth knowing about "Oncolytic virus therapy"

Oncolytic virus therapy is an innovative cancer treatment that uses specially engineered viruses to selectively infect and destroy tumor cells while sparing healthy tissue.

What is Oncolytic Virus Therapy?

Oncolytic virus therapy (also known as oncolytic virotherapy) is a modern approach in cancer medicine that uses naturally occurring or genetically engineered viruses to selectively infect and destroy cancer cells. The term derives from the Greek words “onkos” (tumor) and “lysis” (dissolution). Unlike conventional chemotherapy, this method precisely targets cancer cells while largely sparing surrounding healthy tissue.

Mechanism of Action

Oncolytic viruses exploit specific characteristics of tumor cells that make them more susceptible to viral infection than normal cells. Cancer cells frequently have impaired antiviral defense mechanisms, which allows oncolytic viruses to replicate preferentially within them.

Selective infection: The virus recognizes and preferentially infects tumor cells, largely sparing healthy tissue.
Viral replication: Inside the tumor cell, the virus replicates until the cell is destroyed through lysis (rupture).
Immune activation: When tumor cells rupture, they release antigens that can activate the immune system and trigger a systemic anti-tumor response, functioning similarly to an in-situ vaccine.
Viral spread: Newly produced viral particles infect neighboring tumor cells, amplifying the therapeutic effect.

Areas of Application

Oncolytic virus therapy is currently being researched for various types of cancer and is already in clinical use in some cases:

Melanoma: The oncolytic herpes simplex virus talimogene laherparepvec (T-VEC) is currently the only oncolytic virus approved by the FDA and EMA, used for advanced melanoma.
Glioblastoma: Clinical trials are investigating its use in this aggressive brain tumor.
Head and neck cancers: Various oncolytic viruses are in early clinical trial phases.
Liver, lung, and pancreatic cancer: Early clinical studies are showing promising results.

Types of Viruses Used

Various virus classes are being investigated or genetically modified for oncolytic therapy:

Herpes simplex viruses (HSV): Among the most well-studied; T-VEC is based on HSV-1.
Adenoviruses: Widely used in clinical trials due to their ease of genetic modification.
Reoviruses: Naturally oncolytic against certain tumor cell types.
Measles viruses: Attenuated strains are being tested in clinical trials.
Vaccinia viruses: Poxvirus-based vectors with high tumor selectivity.

Combination with Other Therapies

A highly promising approach is the combination of oncolytic virus therapy with other oncological treatment strategies:

Immune checkpoint inhibitors: Combining with PD-1 or CTLA-4 inhibitors can enhance the immune response against the tumor.
Chemotherapy: Synergistic effects have been observed in preclinical studies.
Radiation therapy: The combination may improve response rates.

Side Effects and Safety

Oncolytic virus therapy is generally considered well-tolerated compared to classical chemotherapy. Typical side effects include:

Flu-like symptoms such as fever, chills, and fatigue
Local reactions at the injection site (redness, swelling, pain)
Rarely: systemic infections, particularly in immunocompromised patients

Genetically engineered viruses are designed to severely limit their ability to spread uncontrollably throughout the body, improving the overall safety profile.

Current State of Research

Oncolytic virus therapy is the subject of intense worldwide research. Hundreds of clinical trials are currently underway to establish efficacy and safety across various tumor types. The combination with immunotherapy is considered one of the most promising approaches in modern oncology.

References

Kaufman, H.L. et al. - Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 14(9):642-662 (2015). Available on PubMed.
Andtbacka, R.H.I. et al. - Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 33(25):2780-2788 (2015). Available on PubMed.
Cattaneo, R. et al. - Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nature Reviews Microbiology, 6(7):529-540 (2008). Available on PubMed.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.